



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mazolevimab

Cat. No.:	HY-P99727
CAS No.:	2419087-89-9
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Mazolevimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies ^{[1][2]} .																
In Vitro	Mazolevimab (0.01-100 µg/mL) shows cytotoxicity to CVS-11 infected BSR cells with dose-dependent manner, but without effecting on uninfected BSR cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
In Vivo	<p>Mazolevimab (0.03-1.0 mg/kg; i.m.; single dose) improves the survival rate of rabies virus (RABV) infected hamsters with dose-dependent manner^[1].</p> <p>Mazolevimab (0.003-1 mg/kg; i.m.; single dose) improves the survival rate of RABV infected hamsters with dose-dependent manner. Mazolevimab (0.003-0.03 mg/kg) has insignificant interference with the serum RVNA level of Syrian hamsters without virus infection^[2].</p> <p>Mazolevimab (0.03-1 mg/kg; i.m.; single dose) has protective effect in beagles infected with RABV (BD06)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>RABV infected Syrian hamster^[1].</td> </tr> <tr> <td>Dosage:</td> <td>0.03, 0.1, 0.3 and 1.0 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Right gastrocnemius muscle injection; single dose.</td> </tr> <tr> <td>Result:</td> <td>Improved the survival rate.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06)^[2].</td> </tr> <tr> <td>Dosage:</td> <td>0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Right gastrocnemius muscle or masseter muscle injection; single dose.</td> </tr> <tr> <td>Result:</td> <td>Improved survival rate and had protective effect.</td> </tr> </table>	Animal Model:	RABV infected Syrian hamster ^[1] .	Dosage:	0.03, 0.1, 0.3 and 1.0 mg/kg.	Administration:	Right gastrocnemius muscle injection; single dose.	Result:	Improved the survival rate.	Animal Model:	10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06) ^[2] .	Dosage:	0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.	Administration:	Right gastrocnemius muscle or masseter muscle injection; single dose.	Result:	Improved survival rate and had protective effect.
Animal Model:	RABV infected Syrian hamster ^[1] .																
Dosage:	0.03, 0.1, 0.3 and 1.0 mg/kg.																
Administration:	Right gastrocnemius muscle injection; single dose.																
Result:	Improved the survival rate.																
Animal Model:	10 two-month-old female Syrian hamsters/six-month-old beagles infected with RABV (BD06) ^[2] .																
Dosage:	0.003, 0.01, 0.03, 0.1, 0.3 and 1 mg/kg.																
Administration:	Right gastrocnemius muscle or masseter muscle injection; single dose.																
Result:	Improved survival rate and had protective effect.																

REFERENCES

- [1]. Chao TY, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.
- [2]. Chao TY, et al. In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. Trop Med Infect Dis. 2020 Feb 21;5(1):31.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA